GRI Bio Inc. Common Stock (GRI)
Stock · NASDAQ · Health Care
$1.38as of 10/16/2026
Price chart
Active signals
GRI Signal Track Record
How signals performed across all stocks →What GRI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 26 | -23.2% | 27% | October 8, 2026 |
| Bollinger Band Breakout | 18 | -22.7% | 17% | September 3, 2026 |
| Volume Spike | 12 | -19.5% | 17% | September 3, 2026 |
| Any 20-session window (baseline) | -16.4% | 27% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GRI
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idi…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 3
- Website
- www.gribio.com/
Fundamentals
- 1-day range
- $1.38$1.45
- Market cap
- $2.74M
- P/E (trailing)
- 0.04
- P/E (forward)
- -0.70
- EPS (trailing)
- $-51.65
- Dividend yield
- —
- Beta
- -1.09
- Avg. volume
- 328.0K
Forecasts
2 analyst ratings
GRI Bio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- GRIGRI Bio Inc. Common Stock$1.38▼ 1.43%Market cap $2.74MP/E 0.04$1.36$64.12
- SHPHShuttle Pharmaceuticals Holdings Inc. Common Stock$5.08▼ 8.80%Market cap $2.79MP/E 43.60$2.58$55.9
- ARTLArtelo Biosciences Inc. Common Stock$2.7▼ 1.46%Market cap $2.62MP/E —$2.92$179.19
- CDTCDT Equity Inc. Common Stock$0.235▲ 12.44%Market cap $2.54MP/E —$0.1813$28,125
- SBFMSunshine Biopharma Inc. Common Stock$0.222▼ 3.48%Market cap $2.97MP/E —$0.4117$24.3
- OGENOragenics Inc. Common Stock$0.43▼ 2.27%Market cap $2.45MP/E 0.56$0.43$1.45
- DCOYDecoy Therapeutics Inc. Common Stock$1.17▼ 4.88%Market cap $2.40MP/E —$2.01$55.92
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GRI GRI Bio Inc. Common Stock | $2.74M | 0.04 | $1.38 | ▼ 1.43% | $1.36$64.12 |
| SHPH Shuttle Pharmaceuticals Holdings Inc. Common Stock | $2.79M | 43.60 | $5.08 | ▼ 8.80% | $2.58$55.9 |
| ARTL Artelo Biosciences Inc. Common Stock | $2.62M | — | $2.7 | ▼ 1.46% | $2.92$179.19 |
| CDT CDT Equity Inc. Common Stock | $2.54M | — | $0.235 | ▲ 12.44% | $0.1813$28,125 |
| SBFM Sunshine Biopharma Inc. Common Stock | $2.97M | — | $0.222 | ▼ 3.48% | $0.4117$24.3 |
| OGEN Oragenics Inc. Common Stock | $2.45M | 0.56 | $0.43 | ▼ 2.27% | $0.43$1.45 |
| DCOY Decoy Therapeutics Inc. Common Stock | $2.40M | — | $1.17 | ▼ 4.88% | $2.01$55.92 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga · 10/2/2026
- GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF SummitYahoo · 9/28/2026
- GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?Yahoo · 9/14/2026
- UPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To BuyBenzinga · 9/14/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 28.2K
- Total value held
- $64.7K
- Institutional holders
- 6
- Unknown18.4K
- Unknown8.7K
- Unknown1.1K
- Unknown7
- Unknown4
- Unknown2
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
GRI Bio to Present IPF Data at 10th IPF Summit
GRI Bio announced it will present insights on immune modulation and Phase 2a development for idiopathic pulmonary fibrosis (IPF) at the 10th IPF Summit. This upcoming event provides a key update on the company's clinical progress. The stock is currently trading well below its 52-week high, with analysts maintaining a wide range of price targets.
GRI Bio to Present IPF Data at 10th IPF Summit. GRI Bio announced it will present insights on immune modulation and Phase 2a development for idiopathic pulmonary fibrosis (IPF) at the 10th IPF Summit. This upcoming event provides a key update on the company's clinical progress. The stock is currently trading well below its 52-week high, with analysts maintaining a wide range of price targets.